Close Menu

NEW YORK (GenomeWeb) – Cofactor Genomics announced today that it has partnered with cancer drug developer FLX Bio to create a novel RNA-based immuno-oncology (IO) analysis platform.

According to Cofactor, the platform — called Cofactor Paragon — will be developed using its Sigmund RNA signature analysis technology and RNA assay development expertise, along with FLX Bio's purified immune cells, validation samples, and tumor samples.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Dec
17
Sponsored by
Thermo Fisher Scientific

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.